Tag: Alexion Pharmaceuticals

March 27, 2017 Off

Alexion Pharmaceutical name new CEO

By Dino Mustafić

Alexion Pharmaceuticals’s Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, to succeed David R. Brennan, who has led the company as Interim CEO since December 2016.

March 8, 2017 Off

Alexion waits for FDA’s OK for generalized myasthenia gravis drug

By Dino Mustafić

U.S. Food and Drug Administration(FDA) has accepted for review the Alexion Pharmaceuticals’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.